Hyperthyroidism incidence in a large population-based study in northeastern Italy.
hyperthyroidism
incidence
iodine
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
21
07
2023
accepted:
18
10
2023
medline:
19
10
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
epublish
Résumé
An improvement in iodine status in Veneto Region has been documented in the last decade. We aimed at estimating the incidence of hyperthyroidism in the Veneto Region (Italy) over the period 2013-2022. Retrospective population-based study conducted in Veneto (4.9 million people) using the population registry, an administrative health database. Between 2012 and 2022, hyperthyroidism incidence was defined thank to a health-care co-payment exemption for hyperthyroidism or any hospital diagnosis of hyperthyroidism. Incident hyperthyroidism was defined from 2013 to 2022 to exclude prevalent cases. Standardized incidence rates (IRs) were reported by age, sex, and etiology of thyroid hyperfunction too. We identified 26,602 incident cases (IR of 54.38 per 100,000 person-years, 2.47-fold higher in females than in males). IR decreased from 69.87 (95% CI: 67.49, 72.25) in 2013 to 42.83 (95% CI: 40.99, 44.66) in 2022. In 2020, an out-of-trend decrease in hyperthyroidism incidence was documented, corresponding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic outbreak, with a realignment to the trend in the subsequent years. The annual percentage change according to the cause of hyperthyroidism was as follows: -6.62% (95% CI: 8.47, 4.73) (P < 0.0001) in toxic multinodular goiter, -7.56% in toxic uninodular goiter (95% CI: 10.54, 4.48) (P < 0.001) and -4.70% (95% CI: 6.33, 3.04) in toxic diffuse goiter (Graves' disease) (P < 0.001). We documented a decline in the incidence of hyperthyroidism in Veneto Region, paralleling the improvement of the iodine status, thanks to a long and sustained iodine prophylaxis campaign. SARS-CoV-2 pandemic and vaccination campaign did not change the declining trend of hyperthyroidism incidence in our study region. An improvement in iodine status in the population residing in the Veneto region has been documented in the last decade, thanks to a nationwide voluntary iodine prophylaxis program running since 2005, but its impact on the epidemiology of thyroid disease has never been documented. This is the largest study on the incidence rates of hyperthyroidism carried out in Italy and covers the longest observation period among all regionwide population-based studies of hyperthyroidism in our country. We documented a reduction in the incidence of hyperthyroidism, which was more pronounced in nodular goiter diagnosis but involved also toxic diffuse goiter. The decline in the incidence of hyperthyroidism in Veneto Region shows the efficacy and safety of the iodine prophylaxis campaign.
Identifiants
pubmed: 37855396
doi: 10.1530/EC-23-0292
pii: EC-23-0292
pmc: PMC10692690
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Eur Thyroid J. 2018 Aug;7(4):167-186
pubmed: 30283735
Clin Endocrinol (Oxf). 1995 Jul;43(1):55-68
pubmed: 7641412
Wien Klin Wochenschr. 2021 Mar;133(5-6):182-187
pubmed: 32377868
Thyroid. 1999 Jan;9(1):33-8
pubmed: 10037074
Arch Intern Med. 2000 Feb 28;160(4):526-34
pubmed: 10695693
Thyroid. 1994 Spring;4(1):107-28
pubmed: 8054857
J Clin Endocrinol Metab. 2022 May 17;107(6):e2324-e2330
pubmed: 35235663
Nat Rev Endocrinol. 2018 May;14(5):301-316
pubmed: 29569622
J Endocrinol Invest. 2016 Dec;39(12):1445-1451
pubmed: 27465670
Immunol Res. 2021 Apr;69(2):129-138
pubmed: 33914231
Popul Health Metr. 2016 Nov 8;14:39
pubmed: 27833458
Clin Endocrinol (Oxf). 2013 May;78(5):768-76
pubmed: 23421407
Lancet Diabetes Endocrinol. 2023 Apr;11(4):282-298
pubmed: 36848916
Eur J Endocrinol. 1998 Sep;139(3):290-7
pubmed: 9758438
Eur J Nucl Med. 1998 Apr;25(4):367-74
pubmed: 9553166
Endocr Rev. 2009 Jun;30(4):376-408
pubmed: 19460960
Croat Med J. 2011 Oct 15;52(5):615-21
pubmed: 21990079
J Endocrinol Invest. 2004 Sep;27(8):709-13
pubmed: 15636421
Eur J Clin Nutr. 2013 Apr;67(4):366-70
pubmed: 23462940
Hormones (Athens). 2018 Dec;17(4):565-571
pubmed: 30267376
Eur J Endocrinol. 2019 Sep;181(3):255-266
pubmed: 31252413
Eur J Endocrinol. 1995 May;132(5):546-9
pubmed: 7749493
Nutrients. 2020 Aug 11;12(8):
pubmed: 32796531
Clin Endocrinol (Oxf). 2017 Oct;87(4):386-393
pubmed: 28500624
Thyroid. 2017 Apr;27(4):558-566
pubmed: 28059636
Best Pract Res Clin Endocrinol Metab. 2010 Feb;24(1):13-27
pubmed: 20172467
Endocr Pract. 2011 May-Jun;17(3):456-520
pubmed: 21700562
J Endocrinol Invest. 2003 Oct;26(10):991-6
pubmed: 14759072
J Clin Endocrinol Metab. 2013 Mar;98(3):1031-9
pubmed: 23436921
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067
Clin Endocrinol (Oxf). 2019 Nov;91(5):652-659
pubmed: 31400012
Eur J Endocrinol. 2011 May;164(5):801-9
pubmed: 21357288
Thyroid. 2003 Feb;13(2):199-203
pubmed: 12699595
J Clin Endocrinol Metab. 2022 Apr 19;107(5):e2186-e2187
pubmed: 34928376
Endocrine. 2022 Dec;78(3):406-417
pubmed: 35763241